ZEB.TO 1.21GS 12.07BBD.B.TO -0.5MSFT 10.7XLI -0.39XLK -2.04IXC -0.28AMZN 7.47
Eli Lilly & Co. (LLY)

NYSE:LLY

Eli Lilly & Co. (LLY)

1,156.63
+4.09 (0.35%)
as of Jul 15, 2026, 8:00:00 pm Market Open.
220 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJul 15, 2026, 12:00 am

This summary was created by AI, based on 32 opinions in the last 12 months.

Eli Lilly & Co. (LLY) is viewed as a leader in the GLP-1 drug market, especially with anticipated advancements such as an oral version of their weight-loss drug. Analysts highlight the company's strong earnings growth potential, with forecasts predicting growth rates of around 25-50% in the coming years. The stock is at historically high levels and is seen as a robust choice amidst a competitive landscape, particularly compared to Novo Nordisk (NVO). However, some analysts recommend waiting for a pullback before investing due to its current valuation. The consensus leans towards LLY having a strong pipeline and a diversified portfolio, indicating a positive outlook despite recent volatility in the market.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Fair Value
review icon
Similar
NVO
HOLD

Eli Lilly & Co.(LLY)

Mar 15, 2006
Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$56.97

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Aug 25, 2005
This is a part of the market that's lagging. There has been such a slowdown in the growth rates.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$53.50

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jul 13, 2005
Prefers others such as Abbott Labs (ABT-N).
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$56.37

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Eli Lilly & Co.(LLY)

May 03, 2005
Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$59.75

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Mar 15, 2005
A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold.
Photo of George LougheryGeorge LougheryUnlock Rating
$52.70

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Aug 13, 2004
Lots of new products. Rapid profit growth.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$61.57

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Jul 16, 2004
Powerful balance sheet.
Photo of Alan BlakeAlan Blake
Owned
Unlock Rating
$66.30

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Eli Lilly & Co.(LLY)

Apr 16, 2004
Photo of Richard BernstienRichard Bernstien
Owned
Unlock Rating
$72.45

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Eli Lilly & Co.(LLY)

Apr 02, 2002
Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$78.74

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
BUY

Eli Lilly & Co.(LLY)

Dec 10, 2001
Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
Photo of David BurrowsDavid BurrowsUnlock Rating
$81.54

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Oct 30, 2001
Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J.
Photo of Neil MurdockNeil MurdockUnlock Rating
$77.27

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Eli Lilly & Co.(LLY)

Sep 10, 2001
Good pipeline for new drugs but prefers Pfizer.
Photo of Brad WillockBrad WillockUnlock Rating
$77.20

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Eli Lilly & Co.(LLY)

Jun 05, 2001
Prozac about to go generic.
Photo of Ross HealyRoss HealyUnlock Rating
$88.10

Stock price when the opinion was issued

$1156.63

As of Jul 15, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 208 of 208 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ROAD 6.51$103.86
EPD -0.21$37.52
FHN -0.78$24.94
BNY 0$
QBR.B.TO 0.33$66.61

Today's Top Picks

ZEB.TO 1.21$78.75
GS 12.07$1152.07
BBD.B.TO -0.5$14.97
MSFT 10.7$395.63
XLI -0.39$180.06

Popular Articles

Latest Sell Signals

XE 0$
ADBE 3.78$224.56
AMZN 7.47$254.96
UBER 0.59$72.67
EQX.TO -0.24$13.1

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Colin Cieszynski

Colin Cieszynski

SIA Wealth Management

Keith Richards

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like